Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

References

• Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park). 2002;16:4–10.
   PubMed Web of Science ®Google Scholar
• Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol. 2002;3:89–96.
   PubMed Web of Science ®Google Scholar
• Engell-Noerregaard L, Hansen TH, Andersen MH, Thor SP, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009; 58:1–14.
   PubMed Web of Science ®Google Scholar
• Fearnley DB, Whyte LF, Carnoutsos SA, Cook AH, Hart DN. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood. 1999; 93:728–36.
   PubMed Web of Science ®Google Scholar
• Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, . Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137–51.
   PubMed Web of Science ®Google Scholar
• Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196:121–35.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, . Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135–42.
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Fidolfi L, Ballordini M, . Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med. 2006;4:36.
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, . Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13:905–18.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, . Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563–70.
   PubMed Web of Science ®Google Scholar
• Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of alpha-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine. 2008;26:2824–32.
   PubMed Web of Science ®Google Scholar
• Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, Morse MA, . A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood. 2000;96:3499–504.
   PubMed Web of Science ®Google Scholar
• Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas MA, Caron D, . Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol. 2002;72:546–53.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002;21:674–9.
   PubMed Web of Science ®Google Scholar
• Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61:869–72.
   PubMed Web of Science ®Google Scholar
• Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, Thor SP. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964–8.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, . Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004;10:828–39.
   PubMed Web of Science ®Google Scholar
• Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, . Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA. 2002; 99:12275–80.
   PubMed Web of Science ®Google Scholar
• Otto K, Andersen MH, Eggert A, Firat H, Schmidt JD, Langlade-Demoyen P, . Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine. 2005;23:884–9.
   PubMed Web of Science ®Google Scholar
• Sievers E, Albers P, Schmidt-Wolf IG, Marten A. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol. 2004;171:114–9.
   PubMed Web of Science ®Google Scholar
• Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, . Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase I/II trial. J Immunother. 2008;31:771–80.
   PubMed Web of Science ®Google Scholar
• Barfoed AM, Petersen TR, Kirkin AF, Thor SP, Claesson MH, Zeuthen J. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol. 2000;51:128–33.
   PubMed Web of Science ®Google Scholar
• Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci. 2000;910:121–37.
   PubMed Web of Science ®Google Scholar
• Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM . Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 1994;4:35–45.
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Freibe-Hoffmann U, Myers EN, . Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264–272) peptide in the circulation of patients with head and neck cancer. Cancer Res. 2002;62:3521–9.
   PubMed Web of Science ®Google Scholar
• Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, . Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol. 1995;25:1765–9.
   PubMed Web of Science ®Google Scholar
• Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, . Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004;53:633–41.
   PubMed Web of Science ®Google Scholar
• Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, . Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother. 2007;56(9): 1485–99.
   PubMed Web of Science ®Google Scholar
• Reichardt VL, Brossart P, Kanz L. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev. 2004; 18:235–43.
   PubMed Web of Science ®Google Scholar
• Pedersen AE, Thorn M, Gad M, Walter MR, Johnsen HE, Gaarsdal E, . Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol. 2005;61:147–56.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 2001;61:2618–24.
   PubMed Web of Science ®Google Scholar
• Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005;65:5417–27.
   PubMed Web of Science ®Google Scholar
• Maecker B, Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Anderson KC, Nadler LM, . Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol. 2005; 141:558–62.
   PubMed Web of Science ®Google Scholar
• Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, . High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425–33.
   PubMed Web of Science ®Google Scholar
• Thorn M, Wang M, Kloverpris H, Schmidt EG, Fomsgaard A, Wenandy L, . Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. Cancer Immunol Immunother. 2007;56:1755–63.
   Google Scholar
• Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001; 7:3343–8.
   PubMed Web of Science ®Google Scholar
• Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002;62:2600–5.
   PubMed Web of Science ®Google Scholar
• Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, . Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003;9:4743–55.
   PubMed Web of Science ®Google Scholar
• Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, . The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 2003;63:4507–15.
   PubMed Web of Science ®Google Scholar
• Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, Straten Pt, . Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004; 3:173–9.
   PubMed Web of Science ®Google Scholar
• Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004;108:937–41.
   PubMed Web of Science ®Google Scholar
• Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, . The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res. 1998; 18:79–92.
   PubMed Web of Science ®Google Scholar
• Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, . Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000;192:1535–44.
   PubMed Web of Science ®Google Scholar
• Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine. 2006;24:1958–65.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol. 2009;70:481–9.
   PubMedGoogle Scholar
• Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, . Design and use of conditional MHC class I ligands. Nat Med. 2006;12:246–51.
   PubMed Web of Science ®Google Scholar
• Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, . Generation of peptide–MHC class I complexes through UV-mediated ligand exchange. Nat Protoc. 2006;1:1120–32.
   PubMed Web of Science ®Google Scholar
• van OM, Bins A, Elias S, Sein J, Weder P, de Gast G, . On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res. 2004;10:4754–60.
   PubMed Web of Science ®Google Scholar
• Harvey S, Weisman M, O’Dell J, Scott T, Krusemeier M, Visor J, . Chondrex: new marker of joint disease. Clin Chem. 1998;44:509–16.
   PubMed Web of Science ®Google Scholar
• Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.
   PubMed Web of Science ®Google Scholar
• Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, Nielsen L, . Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers. 2007;1–20.
   PubMed Web of Science ®Google Scholar
• Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van VJ, Hombrink P, . Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009;6:520–6.
   PubMed Web of Science ®Google Scholar
• Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol. 2006;50:34–43.
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, . Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798–807.
   PubMed Web of Science ®Google Scholar
• Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother. 2005;1–5.
   Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, . Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12:878–87.
   PubMed Web of Science ®Google Scholar
• Letsch A, Keilholz U, Assfalg G, Mailander V, Thiel E, Scheibenbogen C. Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. Cancer Res. 2003;63:5582–6.
   PubMed Web of Science ®Google Scholar
• Liu LN, Shivakumar R, Allen C, Fratantoni JC. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol Biol. 2008;423:139–53.
   PubMedGoogle Scholar
• Thumann P, Moc I, Humrich J, Berger TG, Schultz ES, Schuler G, . Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods. 2003;277:1–16.
   PubMed Web of Science ®Google Scholar
• Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, . Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006; 55:819–29.
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, . Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004; 64:5934–7.
   PubMed Web of Science ®Google Scholar
• Berntsen A, Brimnes MK, thor Straten P, Svane IM. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose IL-2. J Immunotherapy. In press.
   Google Scholar
• Svane IM, Pedersen AE, Nikolajsen K, Zocca MB. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine. 2008; 26:4716–24.
   Google Scholar
• van Dervliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, . Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res. 2007;13:2100–8.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409–14.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, . Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–8.
   PubMed Web of Science ®Google Scholar
• Nistico P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, . Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer. 2008;124:130–9.
   Web of Science ®Google Scholar